← Leaderboards
Michael C. Milone
Children'S Hosp Of Philadelphia
$6,962,068
Attributed
$20,397,309
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.9M · FY2017–25$5M$3.8M$2.5M$1.3M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,397,309 · 5
By mechanism
U01$14,843,451 · 1
U54$1,786,272 · 1
R01$1,683,000 · 1
P01$1,636,188 · 1
R21$448,398 · 1
Top collaborators
- Vijay Bhoj5 shared
- Alfred L. Garfall5 shared
- Carl H. June5 shared
- James F Markmann5 shared
- Ali Naji5 shared
- Valder R Arruda2 shared
- David P Richman2 shared
- Ben J Samelson-Jones2 shared
Most similar at Children'S Hosp Of Philadelphia
Same institution · by research overlap
- Daniel J. Campbell$19,196,457
- Ben J Samelson-Jones$4,366,849
- Ross England$184,896
Others in their field
Other Emerging Leaders on “T-Lymphocyte”
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$20,250,477
- Crystal Mackall · Children'S Hosp Of Philadelphia$16,367,876
- Wilton B Williams · Duke University$16,226,847
- Gary Fanger · Rise Therapeutics, Llc$15,372,982
- Aaron Esser-Kahn · University Of Chicago$13,378,548
Research focus
T-LymphocyteAntigensB-LymphocytesIn VivoCellsChimeric Antigen Receptor T CellsMalignant NeoplasmsChimeric Antigen ReceptorSafetyCell MaturationCd19 GenePlasma CellsAntibodiesImmuneCar T Cell TherapyInfusion ProceduresImmunityDesignToxic EffectImmunotherapyCell TherapyIsoantibodiesCell LineageAutologous
Grant awards (15)
Autologous chimeric antigen receptor engineered T cell immunotherapy for desensitization in patients awaiting kidney transplantation$4,303,502
U01 · FY2025 · AI
Improving response durability after CAR T cell therapy for multiple myeloma$564,221
P01 · FY2025 · CA · contact PI
Autologous chimeric antigen receptor engineered T cell immunotherapy for desensitization in patients awaiting kidney transplantation$3,825,129
U01 · FY2024 · AI
Improving response durability after CAR T cell therapy for multiple myeloma$565,591
P01 · FY2024 · CA · contact PI
Autologous chimeric antigen receptor engineered T cell immunotherapy for desensitization in patients awaiting kidney transplantation$764,364
U01 · FY2023 · AI
Improving response durability after CAR T cell therapy for multiple myeloma$506,376
P01 · FY2023 · CA · contact PI
Autologous chimeric antigen receptor engineered T cell immunotherapy for desensitization in patients awaiting kidney transplantation$2,975,228
U01 · FY2022 · AI
Autologous chimeric antigen receptor engineered T cell immunotherapy for desensitization in patients awaiting kidney transplantation$2,975,228
U01 · FY2021 · AI
Engineering cellular immunotherapy to modulate immune responses in hemophilia$416,250
R01 · FY2020 · HL
Project 3$1,786,272
U54 · FY2019 · CA · contact PI
Engineering cellular immunotherapy to modulate immune responses in hemophilia$416,250
R01 · FY2019 · HL
Antigen-specific treatment of myasthenia gravis: Chimeric autoantibody receptor T cells targeting autoimmune B cells$197,456
R21 · FY2019 · NS
Engineering cellular immunotherapy to modulate immune responses in hemophilia$416,250
R01 · FY2018 · HL
Antigen-specific treatment of myasthenia gravis: Chimeric autoantibody receptor T cells targeting autoimmune B cells$250,942
R21 · FY2018 · NS
Engineering cellular immunotherapy to modulate immune responses in hemophilia$434,250
R01 · FY2017 · HL